Displaying 11 (all) recruiting clinical trials.
-
Prospective Database of Clinical Outcomes Following Cryotherapy for ablation of clinically localized prostate cancer
Primary Objective: To record the treatment results and impact on clinical parameters following of Cryotherapy for ablation of clinically localized prostate cancer. Primary outcome variables ...Phase N/A
Non-Interventional
-
A PHASE I/IB SINGLE ARM STUDY OF TWO FRACTION SBRT WITH DOMINANT LESION SIB FOR THE TREATMENT OF LOCALIZED PROSTATE CANCER
Phase I/IB, single arm trial of Two-Fraction SBRT with an MRI directed, dominant intraprostatic lesion, simultaneous integrated boost based on genomic classification in the ...Phase
Interventional
-
A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors
This is a study testing MOMA-313, a drug that blocks a protein called DNA polymerase theta (Pol?) for prostate cancer with a genetic feature called ...
Phase
Interventional
-
A Phase 2 Open-label Study Evaluating Dosimetry Randomized Dose Optimization Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants with PSMA PET-Positive Castration-Resistant Prostate Cancer
This is a three-part study which includes biodistribution (Part 1), dose optimization (Part 2) to determine the optimal dose of Ac-225 rosopatamab tetraxetan to be ...Phase
Interventional
-
A PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF MR-LINAC- GUIDED RADIOTHERAPY AS SALVAGE TREATMENT AFTER EXTERNAL BEAM RADIOTHERAPY RECURRENCE (TUMORNATOR II)
This Phase 2 study is testing how using a special imaging technique called the Elekta Unity MR-linac system can be safe and effective for patients ...
Phase
Interventional
-
A Phase 3 Randomized Double-blind Placebo-controlled Study of Pasritamig (JNJ-78278343) a T-cell-redirecting Agent Targeting Human Kallikrein 2 + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for ...Phase
Interventional
-
Phase 1 Dose-Escalation Study of KTX-2001 (an NSD2 Inhibitor) Alone and in Combination with Darolutamide for Metastatic Castration-Resistant Prostate Cancer
This is a multicenter, open-label Phase 1 study in participants with metastatic castration-resistant prostate cancer (mCRPC) to investigate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and ...Phase
Interventional
-
A Phase 2a Multicenter Dose Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
This is a Phase 2 study testing a treatment called SYNC-T Therapy SV-102 in adult men with metastatic castration-resistant prostate cancer (mCRPC). SYNC-T Therapy SV-102 ...
Phase
Interventional
-
A Phase 3 Randomized Open-label Study of Pasritamig (JNJ-78278343) a T-cell-redirecting Agent Targeting Human Kallikrein 2 With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate CancerPhase
Interventional
-
A PHASE 1 OPEN-LABEL MULTICENTER STUDY OF JANX007 IN SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
This study is a first-in-human (FIH), Phase 1, open-label, multicenter study to assess the safety, tolerability, PK, PD, and preliminary efficacy of JANX007 administered as ...Phase
Interventional
